{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012604","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.945984+00:00","generated_at":"2026-05-17T08:16:14.216982+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bone Biologics CEO updates on NB1 trial enrollment, shelf life extension, and $5M offering","bullets":["Clinical trial enrollment slower than anticipated; expects to complete enrollment by year-end 2025.","Achieved 18-month shelf life for NB1 protein, up from 12 months; plan to extend to 24 months.","Filed U.S. patent application in June 2025 for proprietary rhNELL-1 compositions for bone conditions.","Raised $5M gross in June public offering; expects cash to fund operations into Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012604","json":"https://secwatch.observer/filing/0001493152-25-012604.json","markdown":"https://secwatch.observer/filing/0001493152-25-012604.md","text":"https://secwatch.observer/filing/0001493152-25-012604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315225012604/0001493152-25-012604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315225012604/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:16:14.216982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}